FDA
-
-
-
-
-
-
-
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
-
-
-
-
-
-
-
Lexicon presents additional pilavapadin data for diabetic nerve pain
-
-
-
-
-
-
-
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
-
-
-
-
-
-
-
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
-
-
-
-
-
-
-
Lexicon Pharmaceuticals (LXRX) PT Lowered to $4 at H.C. Wainwright
-
-
-
-
-
-
-
Lexicon Pharmaceuticals (LXRX) PT Lowered to $6 at H.C. Wainwright
-
-
-
-
-
-
-
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
-
327,748 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

